A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

NCT05145179 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Receptor, ErbB-2

Interventions

DRUG: SSGJ-705

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.